Recent advances in understanding GLP-1R (glucagon-like peptide-1 receptor) function.

Type 2 diabetes is a major global health problem and there is ongoing research for new treatments to manage the disease. The GLP-1R (glucagon-like peptide-1 receptor) controls the physiological response to the incretin peptide, GLP-1, and is currently a major target for the development of therapeutics owing to the broad range of potential beneficial effects in Type 2 diabetes. These include promotion of glucose-dependent insulin secretion, increased insulin biosynthesis, preservation of β-cell mass, improved peripheral insulin sensitivity and promotion of weight loss. Despite this, our understanding of GLP-1R function is still limited, with the desired spectrum of GLP-1R-mediated signalling yet to be determined. We review the current understanding of GLP-1R function, in particular, highlighting recent contributions in the field on allosteric modulation, probe-dependence and ligand-directed signal bias and how these behaviours may influence future drug development.

[1]  P. Sexton,et al.  Small Molecule Allosteric Modulation of the Glucagon-Like Peptide-1 Receptor Enhances the Insulinotropic Effect of Oxyntomodulin , 2012, Molecular Pharmacology.

[2]  P. Sexton,et al.  Allosteric Modulation of Endogenous Metabolites as an Avenue for Drug Discovery , 2012, Molecular Pharmacology.

[3]  P. Sexton,et al.  Second Extracellular Loop of Human Glucagon-like Peptide-1 Receptor (GLP-1R) Has a Critical Role in GLP-1 Peptide Binding and Receptor Activation* , 2011, The Journal of Biological Chemistry.

[4]  P. Sexton,et al.  Second Extracellular Loop of Human Glucagon-like Peptide-1 Receptor (GLP-1R) Differentially Regulates Orthosteric but Not Allosteric Agonist Binding and Function* , 2011, The Journal of Biological Chemistry.

[5]  K. Coopman,et al.  Residues within the transmembrane domain of the glucagon-like peptide-1 receptor involved in ligand binding and receptor activation: modelling the ligand-bound receptor. , 2011, Molecular endocrinology.

[6]  Ruben Abagyan,et al.  Refinement of Glucagon-like Peptide 1 Docking to Its Intact Receptor Using Mid-region Photolabile Probes and Molecular Modeling* , 2011, The Journal of Biological Chemistry.

[7]  P. Sexton,et al.  Modulation of the Glucagon-Like Peptide-1 Receptor Signaling by Naturally Occurring and Synthetic Flavonoids , 2011, Journal of Pharmacology and Experimental Therapeutics.

[8]  P. Sexton,et al.  Allosteric modulation of G protein-coupled receptors: A pharmacological perspective , 2011, Neuropharmacology.

[9]  Francis S. Willard,et al.  Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist Stimulates Insulin Secretion in Rodents and From Human Islets , 2010, Diabetes.

[10]  P. Sexton,et al.  Allosteric Ligands of the Glucagon-Like Peptide 1 Receptor (GLP-1R) Differentially Modulate Endogenous and Exogenous Peptide Responses in a Pathway-Selective Manner: Implications for Drug Screening , 2010, Molecular Pharmacology.

[11]  Qing Liu,et al.  Non-peptidic glucose-like peptide-1 receptor agonists: aftermath of a serendipitous discovery , 2010, Acta Pharmacologica Sinica.

[12]  L. Olansky.  Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis? , 2010, Cleveland Clinic Journal of Medicine.

[13]  Laurence J Miller,et al.  Spatial Approximations between Residues 6 and 12 in the Amino-terminal Region of Glucagon-like Peptide 1 and Its Receptor , 2010, The Journal of Biological Chemistry.

[14]  F. Reimann.  Molecular mechanisms underlying nutrient detection by incretin-secreting cells , 2010, International dairy journal.

[15]  C. Rosebraugh,et al.  Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy. , 2010, The New England journal of medicine.

[16]  M. Christensen,et al.  Once-Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide? , 2010, Current diabetes reports.

[17]  N. Irwin,et al.  Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline. , 2010, European journal of pharmacology.

[18]  J. Bockaert,et al.  GLP-1 Mediates Antiapoptotic Effect by Phosphorylating Bad through a β-Arrestin 1-mediated ERK1/2 Activation in Pancreatic β-Cells , 2009, The Journal of Biological Chemistry.

[19]  Lotte Bjerre Knudsen,et al.  Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor* , 2009, The Journal of Biological Chemistry.

[20]  Laurence J Miller,et al.  Molecular Basis of Glucagon-like Peptide 1 Docking to Its Intact Receptor Studied with Carboxyl-terminal Photolabile Probes* , 2009, The Journal of Biological Chemistry.

[21]  A. Barnett.  New treatments in type 2 diabetes: a focus on the incretin‐based therapies , 2009, Clinical endocrinology.

[22]  Andrew A. Young,et al.  Boc5, a Non-Peptidic Glucagon-Like Peptide-1 Receptor Agonist, Invokes Sustained Glycemic Control and Weight Loss in Diabetic Mice , 2008, PloS one.

[23]  J. Olefsky,et al.  β-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic β cells , 2008, Proceedings of the National Academy of Sciences.

[24]  Kjeld Madsen,et al.  Crystal Structure of the Ligand-bound Glucagon-like Peptide-1 Receptor Extracellular Domain* , 2008, Journal of Biological Chemistry.

[25]  P. Flatt,et al.  Incretin hormone mimetics and analogues in diabetes therapeutics. , 2007, Best practice & research. Clinical endocrinology & metabolism.

[26]  J. Holst,et al.  Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor. , 2007, Bioorganic & medicinal chemistry letters.

[27]  T. Schwartz,et al.  Oxyntomodulin Differentially Affects Glucagon-Like Peptide-1 Receptor β-Arrestin Recruitment and Signaling through Gα , 2007, Journal of Pharmacology and Experimental Therapeutics.

[28]  C. Anderson,et al.  Biological activity of AC3174, a peptide analog of exendin-4 , 2007, Regulatory Peptides.

[29]  D. Drucker,et al.  Biology of incretins: GLP-1 and GIP. , 2007, Gastroenterology.

[30]  Jeppe Sturis,et al.  Small-molecule agonists for the glucagon-like peptide 1 receptor , 2007, Proceedings of the National Academy of Sciences.

[31]  Kaixian Chen,et al.  A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice , 2007, Proceedings of the National Academy of Sciences.

[32]  T. Schwartz,et al.  Characterization of glucagon-like peptide-1 receptor beta-arrestin 2 interaction: a high-affinity receptor phenotype. , 2005, Molecular endocrinology.

[33]  E. Gulve,et al.  Chemistry and biochemistry of type 2 diabetes. , 2004, Chemical reviews.

[34]  D. Donnelly,et al.  Met-204 and Tyr-205 are together important for binding GLP-1 receptor agonists but not their N-terminally truncated analogues. , 2004, Protein and peptide letters.

[35]  H. Noushmehr,et al.  Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. , 2003, Endocrinology.

[36]  D. Donnelly,et al.  A model for receptor–peptide binding at the glucagon‐like peptide‐1 (GLP‐1) receptor through the analysis of truncated ligands and receptors , 2003, British journal of pharmacology.

[37]  B. Wulff,et al.  Different domains of the glucagon and glucagon‐like peptide‐1 receptors provide the critical determinants of ligand selectivity , 2003, British journal of pharmacology.

[38]  D. Donnelly,et al.  The glucagon‐like peptide‐1 receptor binding site for the N‐terminus of GLP‐1 requires polarity at Asp198 rather than negative charge , 2002, FEBS letters.

[39]  R. Rudolph,et al.  In vitro folding, functional characterization, and disulfide pattern of the extracellular domain of human GLP-1 receptor. , 2002, Biophysical chemistry.

[40]  C. Östenson,et al.  Different domains in the third intracellular loop of the GLP-1 receptor are responsible for Gαs and Gαi/Gαo activation , 2001 .

[41]  M. Wheeler,et al.  Characterization of glucagon-like peptide-1 receptor-binding determinants. , 2000, Journal of molecular endocrinology.

[42]  L. B. Knudsen,et al.  Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. , 2000, Journal of medicinal chemistry.

[43]  Andreas Wilmen,et al.  The isolated N‐terminal extracellular domain of the glucagon‐like peptide‐1 (GLP)‐1 receptor has intrinsic binding activity , 1996, FEBS letters.

[44]  A. Joyner,et al.  Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor gene , 1996, Nature Medicine.

[45]  T. Kenakin,et al.  Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. , 1995, Trends in pharmacological sciences.

[46]  D. Drucker,et al.  Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[47]  J. Shaw,et al.  Global estimates of the prevalence of diabetes for 2010 and 2030. , 2010, Diabetes research and clinical practice.

[48]  S. Chae,et al.  Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery. , 2008, Bioconjugate chemistry.

[49]  G. Holz.  Epac: A new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell. , 2004, Diabetes.

[50]  M. Bernier,et al.  Pancreatic Glucagon-Like Peptide-1 Receptor Couples to Multiple G Proteins and Activates Mitogen-Activated Protein Kinase Pathways in Chinese Hamster Ovary Cells * , 1999 .

[51]  C. Strader,et al.  The amino terminal domain of the glucagon-like peptide-1 receptor is a critical determinant of subtype specificity. , 1996, Receptors & channels.

[52]  B. Göke,et al.  Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. , 1995, Digestion.

[53]  J. Holst,et al.  Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. , 1993, The Journal of clinical investigation.